Virtuix Expands Into AI-Assisted Neurodivergent Therapy Through Rutgers University Collaboration
Rhea-AI Summary
Virtuix (NASDAQ: VTIX) announced a collaboration with Rutgers University, which has deployed the Omni One omni-directional treadmill at WINLAB. The project focuses on AI-assisted neurodivergent therapy and immersive behavioral analytics, including autism therapy for children.
The initiative studies how full-body movement in XR with adaptive AI may affect attention, engagement, and spatial interaction. Virtuix views healthcare and therapeutic uses as a growing opportunity alongside its consumer and defense focus. The global ASD treatment market is projected to reach over $18 billion by 2034.
AI-generated analysis. Not financial advice.
Positive
- Rutgers University deploys Omni One for AI-assisted neurodivergent therapy research
- Collaboration extends Virtuix applications into healthcare and therapeutic research settings
- Second recent university deployment following Florida Gulf Coast University evaluation
- Targets growing ASD treatment market projected above $18 billion by 2034
Negative
- None.
News Market Reaction – VTIX
On the day this news was published, VTIX declined 4.04%, reflecting a moderate negative market reaction. Argus tracked a trough of -19.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $111.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Computer Hardware group appeared in the momentum scanner, suggesting VTIX’s -9.79% pre-news move was stock-specific rather than part of a sector rotation.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | AI VR partnership | Positive | +1.9% | Joined Meta’s “Made for Meta” program and reported strong revenue growth. |
| Feb 03 | AI defense upgrade | Positive | -11.7% | Announced AI-driven terrain tech for defense training with notable adopters. |
AI-tagged announcements have produced mixed reactions, with an average move of -4.91%, indicating investors have not consistently rewarded AI news.
Recent AI-related updates for Virtuix show expansion of its Omni One platform into major ecosystems and advanced training applications. On Feb 17, 2026, the company joined Meta’s “Made for Meta” program and reported 138% YoY revenue growth, with a modestly positive share reaction. On Feb 3, 2026, an AI-driven terrain update for defense training drew a sharply negative move. Today’s AI-assisted therapy collaboration fits this pattern of strategic AI extensions beyond core gaming.
Historical Comparison
AI-tagged news has driven mixed VTIX reactions, averaging -4.91%. This Rutgers AI-therapy collaboration extends the same AI/XR theme into healthcare use cases.
AI-related releases progressed from integrating AI in defense training and Meta’s ecosystem toward applying AI-assisted, movement-centered XR in healthcare and neurodivergent therapy.
Market Pulse Summary
This announcement highlights Virtuix’s push to apply its Omni One platform and AI-enabled XR beyond entertainment and defense, into neurodivergent therapy and behavioral analytics with Rutgers University. The cited ASD market growth to >$18 billion by 2034 underscores the scale of potential healthcare opportunities. Investors may watch for concrete clinical, academic, or commercialization milestones and how these initiatives complement existing defense and consumer strategies.
Key Terms
xr technical
ai-enhanced behavioral therapy medical
omni-directional treadmill technical
autism spectrum disorder (asd) medical
compound annual growth rate financial
AI-generated analysis. Not financial advice.
Rutgers University Deploys Omni One Platform to Explore Movement-Centered XR and AI-Enhanced Behavioral Therapy Applications
Collaboration Broadens Virtuix’s Applications Beyond Traditional Consumer and Defense End Markets
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of immersive full-body virtual reality systems, today announced that Rutgers University has deployed the Omni One omni-directional treadmill platform at WINLAB for research and development focused on AI-assisted neurodivergent therapy and immersive behavioral analytics applications, including autism therapy for children.
The initiative will explore how immersive virtual environments, combined with full-body movement on Omni One and adaptive AI interaction, may enhance engagement and learning outcomes in therapeutic settings beyond traditional approaches that rely primarily on visual and audio interaction.
The collaboration combines Virtuix’s locomotion platform with AI-enhanced immersive environments designed to support movement-centered interactions and spatial navigation. Researchers plan to evaluate patients’ attention, movement patterns, response timing, engagement consistency, and spatial interaction over time.
“We believe movement-centered, AI-enabled virtual reality represents a significant emerging opportunity across therapy, rehabilitation, and other healthcare applications,” said Jan Goetgeluk, Chief Executive Officer of Virtuix. “By introducing full-body movement and AI interaction through Omni One, we are enabling entirely new categories of user engagement beyond traditional VR experiences. We are excited to work with Rutgers University to explore these possibilities.”
“This collaboration allows us to explore how VR immersion combined with full-body locomotion and AI may create new approaches for neurodevelopmental therapy,” said Dr. Yingying Chen, Department Chair and Distinguished Professor of Electrical and Computer Engineering at Rutgers University. “We believe movement-centered immersive systems can open important new directions for engagement within therapeutic environments.”
The Rutgers collaboration represents an important validation of Virtuix’s immersive XR platform within advanced university-led healthcare and therapeutic research environments. The initiative follows a recent Omni One deployment to Florida Gulf Coast University for evaluation in rehabilitation and clinical simulation applications. While Virtuix’s primary focus remains on consumer entertainment and defense applications, the company believes full-body movement within AI-enabled environments may play an increasingly important role across next-generation healthcare and therapeutic applications.
According to Fortune Business Insights, the global autism spectrum disorder (ASD) treatment market is projected to expand from approximately
About Virtuix
Virtuix Inc. (NASDAQ: VTIX) is a leading manufacturer of full-body virtual reality systems for consumer, enterprise, healthcare, and defense markets. The company’s premier portfolio of “Omni” omni-directional treadmills enables users to walk and run in 360 degrees inside video games and other immersive virtual reality applications. With a commitment to innovation, Virtuix continues to push the boundaries of XR, spatial computing, and AI-driven immersive experiences. For more information, visit virtuix.com.
Please visit the Company’s new Investor Relations website at invest.virtuix.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s plans to pursue strategic acquisitions, the potential benefits of any such acquisition, the expected synergies, the potential impact on revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com
Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us
